Breaking News Instant updates and real-time market news.

FOXA

21st Century Fox

$48.82

0.05 (0.10%)

, FOX

21st Century Fox

$48.48

-0.01 (-0.02%)

08:20
01/11/19
01/11
08:20
01/11/19
08:20

Fox does not intend to bid for any regional sports networks Disney may sell

In a regulatory filing, Fox Corporation, a wholly-owned subsidiary of Twenty-First Century Fox (FOXA), disclosed that it intends to commence preliminary discussions with investors in connection with a potential financing consisting of senior unsecured notes. The net proceeds of the notes offering will be principally used to partially fund the dividend payment to the company in the amount of $8.5B in accordance with the amended and restated agreement and plan of merger with Disney (DIS). In connection with these preliminary discussions, Fox confirms that it does not intend to bid for any of the Fox regional sports networks that Disney, or any entity operating on its behalf, may sell as required by the consent decree with the U.S. Department of Justice, the filing stated.

FOXA

21st Century Fox

$48.82

0.05 (0.10%)

FOX

21st Century Fox

$48.48

-0.01 (-0.02%)

DIS

Disney

$112.77

0.06 (0.05%)

  • 05

    Feb

  • 03

    Mar

FOXA 21st Century Fox
$48.82

0.05 (0.10%)

12/07/18
WOLF
12/07/18
INITIATION
Target $16
WOLF
Outperform
21st Century Fox initiated with an Outperform at Wolfe Research
Wolfe Research initiated 21st Century Fox with an Outperform and $16 price target.
01/08/19
LOOP
01/08/19
NO CHANGE
Target $51
LOOP
Buy
21st Century Fox is 'attractive' way to participate in Disney, says Loop Capital
Loop Capital analyst Alan Gould kept his Buy rating and $51 price target on 21st Century Fox (FOXA), saying the stock represents "an attractive way to buy Disney (DIS) and create "New Fox" shares in the spinoff. The analyst also expects the New Fox to have less debt than previously anticipated while benefiting from continued strong growth of the Fox News Channel.
11/29/18
IMPC
11/29/18
NO CHANGE
Target $32
IMPC
Outperform
Disney sale of sports networks should revalue MSG Networks, says Imperial
MSG Networks (MSGN), as the only pure-play regional sports networks security publicly traded, is "vastly under-covered and under-appreciated," Imperial Capital analyst David Miller tells investors in a research note. Disney (DIS) is selling off the Fox Regional Sports Networks, which the company must do per Department of Justice decree issued on June 27, adds the analyst. He believes that as the closest pure-play comparable to these networks, the terminal value of the transaction should lead to a revaluation of MSG Networks in the public markets. Miller keeps an Outperform rating on MSG Networks with a $32 price target.
12/06/18
CHLM
12/06/18
INITIATION
Target $5
CHLM
Buy
Telaria initiated with a Buy at Craig-Hallum
Craig-Hallum analyst Jason Kreyer started coverage of Telaria (TLRA) with a Buy rating and $5 price target. The analyst notes that the company's partnerships with over-the-top streaming providers such as Hulu, Sling (DISH), Sony's (SNE) VUE, Fox (FOXA), A&E, and FuboTV generated about 20% of total revenue last year and he projects it will grow to nearly 60% by 2020. As consumers continue to pivot toward over-the-top subscriptions, Telaria benefits from its agnostic platform that partners with a variety of publishers to monetize video ad content, Kreyer contends.
FOX 21st Century Fox
$48.48

-0.01 (-0.02%)

10/15/18
MSCO
10/15/18
NO CHANGE
Target $135
MSCO
Overweight
Disney shares appear 'compelling' at current levels, says Morgan Stanley
Morgan Stanley analyst Benjamin Swinburne believes Disney (DIS) shares appear "compelling" at a current valuation of under 13x "core" FY20 pro forma EPS given the company's opportunity to maximize the potential of the acquired Fox (FOXA) assets and scale a direct-to-consumer business. He attributes investor reluctance to own Disney shares to uncertainty about its ability to simultaneously execute on a large acquisition, launch a global direct-to-consumer business and grow, but Swinburne sees this "complexity discount" as an opportunity, he tells investors. He maintains an Overweight rating on Disney shares with a $135 price target.
11/08/18
MSCO
11/08/18
NO CHANGE
Target $54
MSCO
Overweight
Morgan Stanley raises 'New Fox' estimates after 21st Century Fox report
Morgan Stanley analyst Benjamin Swinburne said 21st Century Fox's Q1 results reinforced his conviction in his Overweight view, as he believes its strong distribution and ad sales results in the U.S. underscore Fox's pricing power. Following the quarterly report, Swinburne raised his estimates for "New Fox" and increased his price target on 21st Century Fox shares to $54 from $53 based on his value of $13 per share for "New Fox" and $41 per share for "RemainCo." The analyst also noted that Fox's international cable networks came in below his expectations, adding that he believes Disney's (DIS) acquisition of Fox's content production assets and Star India, along with gaining a majority stake in Hulu, are the primary growth drivers.
10/30/18
MSCO
10/30/18
NO CHANGE
Target $95
MSCO
Overweight
WWE shares 'on sale' after pullback, says Morgan Stanley
Morgan Stanley analyst Benjamin Swinburne noted that WWE (WWE) shares are down by over 30% this month, which he sees as a "rare opportunity" to buy shares of a company that he sees having both highly visible earnings growth and growing intellectual property value. He attributes the rapid selloff primarily to a broader market rotation out of risk assets due to rising interest rates and concerns over achieving long-term growth, but he thinks this "does not make sense" given that WWE's EBITDA opportunity "is not a decade away, but rather a year away," Swinburne tells investors. Two contracts underwritten by Comcast (CMCSA) and Fox (FOXA) drive the bulk of its earnings growth and its financial outlook has no immediate exposure to ratings or cord-cutting, Swinburne added. While he trimmed his price target on WWE shares to $95 from $105 after bumping up his investment expectations for 2019, the analyst maintains an Overweight rating on the stock.
DIS Disney
$112.77

0.06 (0.05%)

12/14/18
NEED
12/14/18
NO CHANGE
Target $100
NEED
Buy
Electronic Arts price target lowered to $100 from $150 at Needham
Needham analyst Laura Martin lowered her price target on Electronic Arts (EA) to $100 given the company's less inspiring game release slate in FY20 relative to FY19, noting that the margins on the Star Wars title expected next year are lower than this year's Battlefield because of Disney (DIS) royalties. The analyst also attributes the lower target to the market repricing of stocks "valued at over 4-times enterprise value to sales". Martin is keeping her Buy rating on Electronic Arts given the ownership of its own IP assets, loyalty of "super-fans", lower risk based on its dependence on title "sequels", and the under-40 age demographic of its target market. The analyst adds that while the company does not have a "Sports game creation problem", the same may not be said about action/adventure game creation.
01/02/19
BOFA
01/02/19
NO CHANGE
BOFA
Top 10 US Ideas for Q1 2019 at BofA/Merrill
BofA/Merrill's Alpha Generation Research team introduced its latest Top 10 US Ideas for Q1 2019. The list consists of 9 Buys that are Cigna (CI), Disney (DIS), Equinix (EQIX), Honeywell (HON), Lockheed Martin (LMT), Marvell (MRVL), Procter & Gamble (PG), AT&T (T), and Tapestry (TPR) and 1 Underperform rating which is Campbell Soup (CPB).
01/11/19
MSCO
01/11/19
NO CHANGE
Target $430
MSCO
Overweight
Netflix price target lowered to $430 from $475 at Morgan Stanley
Morgan Stanley analyst Benjamin Swinburne lowered his price target on Netflix (NFLX) shares to $430 from $475 as he factored in his "modestly lower" view on long-term margins and the broader de-rating of the stock in the market. While he currently forecasts 27M global paid net adds in 2019, Swinburne has tempered his 2019 ARPU growth view, noting that Netflix has not implemented broad price increases as of yet. He still believes Netflix's long-term pricing power remains intact, though he is now taking a more conservative approach to ARPU growth in emerging markets longer term. Swinburne keeps an Overweight rating on Netflix, citing the nearly $500B global TV market it has the potential to address and his view that while many traditional TV studio owners, like Disney (DIS), will pivot to streaming, most likely will not.

TODAY'S FREE FLY STORIES

TEL

TE Connectivity

$79.46

-1.78 (-2.19%)

06:11
01/23/19
01/23
06:11
01/23/19
06:11
Earnings
TE Connectivity lowers FY19 adj. EPS view to $5.35-$5.55 from $5.60-$5.80 »

Consensus $5.68. Lowers…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

  • 25

    Feb

  • 28

    May

SNE

Sony

$48.46

-1.705 (-3.40%)

06:09
01/23/19
01/23
06:09
01/23/19
06:09
Periodicals
Sony to move European domicile from UK amid Brexit risk, FT reports »

Sony will re-domicile the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TEL

TE Connectivity

$79.46

-1.78 (-2.19%)

06:07
01/23/19
01/23
06:07
01/23/19
06:07
Earnings
TE Connectivity sees Q2 adj. EPS $1.25-$1.29, consensus $1.38 »

Sees Q2 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

  • 25

    Feb

  • 28

    May

BLPH

Bellerophon

$0.88

-0.0695 (-7.32%)

06:07
01/23/19
01/23
06:07
01/23/19
06:07
Syndicate
Bellerophon 10M share Spot Secondary priced at $.70 »

H.C. Wainwright acted as…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

SRLP

Sprague Resources

$19.31

-0.24 (-1.23%)

06:05
01/23/19
01/23
06:05
01/23/19
06:05
Hot Stocks
Sprague Resources lowers FY18 adjusted EBITDA view to below $110M-$120M »

Sprague CEO David Glendon…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TEL

TE Connectivity

$79.46

-1.78 (-2.19%)

06:05
01/23/19
01/23
06:05
01/23/19
06:05
Earnings
TE Connectivity reports Q1 adj. EPS $1.29, consensus $1.28 »

Reports Q1 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

  • 25

    Feb

  • 28

    May

TEVA

Teva

$18.75

-0.06 (-0.32%)

06:04
01/23/19
01/23
06:04
01/23/19
06:04
Upgrade
Teva rating change  »

Teva upgraded to Neutral…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Feb

UNTY

Unity Bancorp

$19.85

0.065 (0.33%)

06:03
01/23/19
01/23
06:03
01/23/19
06:03
Earnings
Breaking Earnings news story on Unity Bancorp »

Unity Bancorp reports Q4…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CBPX

Continental Building

$25.55

-0.32 (-1.24%)

06:03
01/23/19
01/23
06:03
01/23/19
06:03
Downgrade
Continental Building rating change  »

Continental Building…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ATHX

Athersys

$1.40

-0.03 (-2.10%)

06:02
01/23/19
01/23
06:02
01/23/19
06:02
Hot Stocks
Athersys reports 'positive' results from study of MultiStem cell therapy »

Athersys announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TOL

Toll Brothers

$34.45

-0.5 (-1.43%)

05:57
01/23/19
01/23
05:57
01/23/19
05:57
Downgrade
Toll Brothers rating change  »

Toll Brothers downgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

KBR

KBR

$17.13

-0.48 (-2.73%)

05:56
01/23/19
01/23
05:56
01/23/19
05:56
Hot Stocks
KBR secures contract for K-SAAT »

KBR announced that it has…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

INFY

Infosys

$10.54

-0.14 (-1.31%)

05:54
01/23/19
01/23
05:54
01/23/19
05:54
Hot Stocks
Infosys enters partnership with HPE GreenLake »

Infosys announced that it…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Jan

WY

Weyerhaeuser

$24.55

-0.54 (-2.15%)

05:54
01/23/19
01/23
05:54
01/23/19
05:54
Initiation
Weyerhaeuser initiated  »

Weyerhaeuser initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Feb

SNE

Sony

$48.46

-1.705 (-3.40%)

05:54
01/23/19
01/23
05:54
01/23/19
05:54
Hot Stocks
Sony announces formation of Sony Home Entertainment & Sound Products »

Sony Visual Products…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DHI

D.R. Horton

$36.43

-0.74 (-1.99%)

, LEN

Lennar

$43.48

-0.63 (-1.43%)

05:54
01/23/19
01/23
05:54
01/23/19
05:54
Upgrade
D.R. Horton, Lennar rating change  »

D.R. Horton upgraded to…

DHI

D.R. Horton

$36.43

-0.74 (-1.99%)

LEN

Lennar

$43.48

-0.63 (-1.43%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

  • 25

    Jan

ZNGA

Zynga

$4.33

0.065 (1.53%)

05:53
01/23/19
01/23
05:53
01/23/19
05:53
Periodicals
Zynga founder raising up to $700M for new investment fund, Axios reports »

Zynga founder Mark Pincus…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Feb

YELP

Yelp

$35.37

-0.895 (-2.47%)

05:51
01/23/19
01/23
05:51
01/23/19
05:51
Periodicals
SCOTUS won't hear lawsuit over defamatory Yelp reviews, The Verge reports »

The Supreme Court has…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jan

HII

Huntington Ingalls

$196.46

-3.82 (-1.91%)

05:50
01/23/19
01/23
05:50
01/23/19
05:50
Downgrade
Huntington Ingalls rating change  »

Huntington Ingalls…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Feb

KCDMY

Kimberly-Clark de Mexico

$0.00

(0.00%)

05:49
01/23/19
01/23
05:49
01/23/19
05:49
Downgrade
Kimberly-Clark de Mexico rating change  »

Kimberly-Clark de Mexico…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DDAIF

Daimler AG

$0.00

(0.00%)

05:47
01/23/19
01/23
05:47
01/23/19
05:47
Upgrade
Daimler AG rating change  »

Daimler AG upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CEO

CNOOC

$161.22

-5.52 (-3.31%)

05:44
01/23/19
01/23
05:44
01/23/19
05:44
Hot Stocks
CNOOC announces 2019 business strategy, development plan »

CNOOC announced its…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BHVN

Biohaven Pharmaceutical

$35.83

-1.04 (-2.82%)

, AZN

AstraZeneca

$36.27

-0.28 (-0.77%)

05:43
01/23/19
01/23
05:43
01/23/19
05:43
Hot Stocks
Biohaven allowed to proceed with BHV-3241 Phase 3 clinical trial »

Biohaven Pharmaceutical…

BHVN

Biohaven Pharmaceutical

$35.83

-1.04 (-2.82%)

AZN

AstraZeneca

$36.27

-0.28 (-0.77%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Feb

  • 20

    Feb

ASML

ASML

$159.39

-3.34 (-2.05%)

05:38
01/23/19
01/23
05:38
01/23/19
05:38
Hot Stocks
ASML, Nikon, Carl Zeiss sign agreement to settle all litigation »

Nikon, ASML Holding, and…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

ASLN

Aslan Pharmaceuticals

$3.55

(0.00%)

05:36
01/23/19
01/23
05:36
01/23/19
05:36
Hot Stocks
Aslan says varlitinib pre-clinical data published online in Cancers »

Aslan Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.